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Abstract
Currently, autologous chondrocyte implantation (ACI) is the
most commonly used cell-based therapy for the treatment of
isolated femoral condyle lesions of the knee. A small number of
centres performing ACI have reported encouraging long-term
clinical results, but there is currently a lack of quantitative and
qualitative biochemical data regarding the nature of the repair
tissue. Glycosaminoglycan (GAG) structure influences
physiological function and is likely to be important in the long-
term stability of the repair tissue. The objective of this study was
to use fluorophore-assisted carbohydrate electrophoresis
(FACE) to both quantitatively and qualitatively analyse the GAG
composition of repair tissue biopsies and compare them with
age-matched cadaveric controls. We used
immunohistochemistry to provide a baseline reference for
comparison. Biopsies were taken from eight patients (22 to 52
years old) 1 year after ACI treatment and from four cadavers (20
to 50 years old). FACE quantitatively profiled the GAGs in as
little as 5 μg of cartilage. The pattern and intensity of
immunostaining were generally comparable with the data
obtained with FACE. In the ACI repair tissue, there was a
twofold reduction in chondroitin sulphate and keratan sulphate
compared with age-matched control cartilage. By contrast,
there was an increase in hyaluronan with significantly shorter
chondroitin sulphate chains and less chondroitin 6-sulphate in
repair tissue than control cartilage. The composition of the repair
tissue thus is not identical to mature articular cartilage.
Introduction
Autologous chondrocyte implantation (ACI), using cultured
chondrocytes implanted beneath a periosteal patch, is widely
used to treat cartilage defects [1]. To date, only a small
number of centres, including our own, have investigated the
long-term stability of the repair tissue by means of outcome
measures such as mechanical testing, clinical scores, mag-
netic resonance imaging, and limited histology [2-8]. Although
the results have been encouraging, they have not determined
the compositional changes of the repair tissue which are
known to have major influences on its physiological function.
Detailed biochemical analyses of the repair tissue and their
comparison with native tissue are important considerations.
Glycosaminoglycans (GAGs) are a cartilage component with
important physiological functions. With the exception of
hyaluronan (HA), GAGs are synthesised covalently bound to
core proteins to form proteoglycans such as aggrecan [9].
GAGs endow the tissue with resistance to compressive load-
ing [10,11] and are involved in many biological interactions
[12,13]. Chondroitin sulphate (CS), keratan sulphate (KS),
and HA are three classes of GAGs found in articular cartilage.
As a function of development, age, and disease, these GAGs
exhibit changes in chain length, chain termination, sulphate
ester substitution, and substitution of CS chains for KS chains
on the aggrecan protein core [14-21]. Approximately 80% of
GAGs in adult articular cartilage are CS chains. They are com-
posed of glucuronic acid (GlcA) and N-acetylgalactosaminePage 1 of 10
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the C4 and/or C6 sites of GalNAc. The sugars are linked by a
β1,3-glycosidic bond, and the chain is capped with a GalNAc
residue that is usually sulphated [21]. The ratio of 6-sulphation
to 4-sulphation in CS chains changes with development and
age [14]. For example, foetal CS chains are equally 4- and 6-
sulphated but adult CS chains are highly 6-sulphated. To add
to the complexity of the CS chain, chain size and the terminal
GalNAc may alter too [21]. Foetal CS chains are approxi-
mately 25 kD and almost entirely capped with a 4-sulphated
GalNAc, whereas adult CS chains are approximately 16 kD
and mostly capped with a 4- and 6-sulphated GalNAc [22].
These alterations in sulphation, chain length, and chain termi-
nation may have roles in directing the location or activities of
extracellular matrix proteins.
KS represents 5% to 20% of the GAG chains in articular car-
tilage. KS is composed of galactose (Gal) and N-acetylglu-
cosamine (GlcNAc) linked by a β1,4-glycosidic bond [23,24].
KS chains can be modified by O-sulphation of the hydroxyl
groups but in a much more restricted pattern when compared
with CS. O-sulphation of the hydroxyl groups at the C6 site of
both the Gal and/or the GlcNAc results in un-, mono-, or disul-
phated repeat disaccharides [25]. KS chains demonstrate an
age-related increase in chain length and sulphation [23-25].
HA accounts for 1% to 10% of GAGs in articular cartilage and
is composed of GlcA and GlcNAc linked by a β1,3-glycosidic
bond. Studies investigating the changes in HA in articular car-
tilage during maturation and ageing are limited. One study,
using a radiosorbent assay with large quantities of whole tis-
sue, reported that the molecular mass of HA decreased and
the concentration increased with increasing age [20]. High
concentrations of HA are generally found during development
and the early stages of wound healing and repair [26,27].
To date, the assessment of the proteoglycan and GAG com-
position of ACI repair tissue has been mainly by metachroma-
sia or immunolocalisation techniques [2-5]. Metachromasia
has provided a crude assessment of the repair tissue with a
limited amount of information [2,5]. Immunolocalisation tech-
niques have provided some information about the type and
distribution of GAGs (mainly KS and CS) but little information
about their chemistry or quantitation [3,4]. Biochemical analy-
ses will always be restricted by the limited repair tissue availa-
ble in humans and the small biopsy size (250 μg).
Consequently, it would be advantageous to have a technique
that could analyse GAG content sensitively in small samples
of tissue. At present, the methods available for analysing
GAGs are generally crude and require large amounts of start-
ing material (5 to 100 mg) [18-20,28-30]. The dimethylmeth-
ylene blue assay is widely used for the quantitation of total
sulphated GAGs [28], but it does nothing to differentiate
between types of GAGs and it can also be inaccurate due to
interference from polyanions from other sources. Other tech-
niques, such as the uronic acid assay [29], provide little infor-
mation about the GAG population and can be time-
consuming. Fluorophore-assisted carbohydrate electrophore-
sis (FACE) has evolved recently to be a highly sensitive tech-
nique for profiling GAGs in small amounts of tissue and body
fluids [13,31-34] and has the added advantage of being able
to process a number of samples simultaneously. As an analyt-
ical technique, FACE [13] can provide more information about
GAGs than other techniques such as radiolabeling [30],
nuclear magnetic resonance [21], or high-performance liquid
chromatography [18]. Consequently, FACE could comple-
ment existing immunolocalisation techniques.
The aim of this study was to use FACE to both quantitatively
and qualitatively analyse the GAG composition of ACI repair
tissue biopsies and compare them with age-matched cadav-
eric controls. We have used immunohistochemistry to provide
a baseline reference for comparison.
Materials and methods
Biopsies of autologous chondrocyte implantation repair 
tissue
In our centre, patients with focal chondral defects of either the
medial femoral condyle or the lateral femoral condyle received
ACI using cultured chondrocytes implanted beneath a perio-
steal patch [1]. Patients underwent arthroscopy and biopsy of
the treated region as part of their routine follow-up at approxi-
mately 1 year post-ACI [3,4]. A single biopsy (1.8 mm in diam-
eter and approximately 5 mm in height) was taken
perpendicularly from the articulating surface through the full
depth of cartilage and subchondral bone from each of eight
patients 1 year post-ACI (Table 1) using a detailed knee map
to identify the repair site. The removal of biopsies from ACI-
treated patients was given ethical approval by the Shropshire
Research and Ethics Committee (UK). All patients gave fully
informed consent.
Biopsies of cadaveric control tissue
Healthy cadaveric knees (22, 30, 40, and 50 years old) were
obtained within 24 hours of death from the UK Human Tissue
Bank with approval by the Trent Research Ethics Committee
(UK). All appeared macroscopically normal apart from the 50-
year old, whose articular cartilage showed slight surface fibril-
lation. Biopsies were taken from each of the medial and lateral
femoral condyles representative of regions most commonly
treated with ACI, as described in the previous paragraph.
Treatment of all biopsies and statistical analysis
All biopsies were snap-frozen in liquid nitrogen-cooled hexane
and stored in liquid nitrogen until studied. Half of each biopsy
was cryosectioned (10-μm sections) for histology and immu-
nohistochemistry. The other half of each biopsy (approximately
250 μg) was digested, divided into eighths, and then analysed
separately by FACE. Results for each biopsy were pooled.
Where appropriate, results are presented as the mean ± thePage 2 of 10
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repair and control tissues were analysed using the Mann-Whit-
ney test (significance level, p ≤ 0.05).
Preparation of glycosaminoglycan saccharides for FACE
The GAGs were extracted from repair tissue and control biop-
sies by means of a previously published methodology [31].
Purified GAGs were depolymerised using GAG-specific
enzymes (Seikagaku Corporation, Tokyo, Japan). HA was
digested into disaccharides (ΔDiHA) using 100 mU/ml of
hyaluronidase (from Streptococcus dysgalactiae) for 1 hour at
37°C [31,32]. CS was digested into disaccharides (6-sul-
phated [ΔDi6S], 4-sulphated [ΔDi4S], and unsulphated
[ΔDi0S]) with 100 mU/ml of chondroitinase ABC (cABC) for
3 hours at 37°C. Sulphation of CS was confirmed by incuba-
tion of cABC-digested samples with 100 mU/ml of chondroi-
tin-4ase and/or chondroitin-6ase for 12 hours at 37°C. The
nonreducing terminal sugars of CS were identified by mercuric
ion treatment [31]. KS was digested as previously described
[13]. Briefly, samples were incubated with 100 mU/ml of kera-
tanase II for 3 hours at 37°C or 100 mU/ml of endo-β-galac-
tosidase for 14 hours. KS digestion was confirmed by
sequential digestion with 100 mU/ml of keratanase II for 3
hours and 100 mU/ml of endo-β-galactosidase for 14 hours
and conversely with 100 mU/ml of endo-β-galactosidase for
14 hours and 100 mU/ml of keratanase II for 3 hours. This
approach will generate four digestion products from the inter-
nal KS chain (unsulphated disaccharide, GlcNAcβ1,3Gal; fuc-
osylated trisaccharide, Galβ1,2 [fucα1,3]GlcNAc6S;
monosulphated disaccharide, Galβ1,4GlcNAc6S; and disul-
phated disaccharide, Gal6Sβ1,4glcNAc6S) and two diges-
tion products that cap the KS chain (sialylated monosulphated
trisaccharide NeuAα2,3Galβ1,4GlcNAc6S and disulphated
trisaccharide NeuAα2,3Gal6Sβ1,4GlcNAc6S).
Fluorotagging and FACE separation
Lyophilised enzyme-digested samples and predefined saccha-
ride standards (Seikagaku Corporation) were reconstituted
with the fluorescent tag, 5 μl of 12.5 mM 2-aminoacridone, in
glacial acetic acid/dimethyl sulfoxide (3:17, vol/vol) and incu-
bated at room temperature for 15 minutes. Five microlitres of
1.25 M sodium cyanoborohydride in distilled deionised water
was added. Samples were incubated at 37°C for 16 hours.
After tagging, 10 μl of 25% glycerol (20% vol/vol final concen-
tration) was used to quench excess sodium cyanoborohy-
dride. Electrophoresis was carried out for 80 minutes at 4°C
as previously described [31].
FACE gel imaging and quantitation
Gels were placed on a transilluminator light box fitted with a
312-nm light source. Fluorescent images were displayed
using a GelDoc-It High CCD [charge-coupled device] Camera
(12-bit depth; Ultra-Violet Products Ltd [UVP], Cambridge,
UK), and the mean pixel density for each product band was
quantified using LabWorks Software (UVP). For each gel,
FACE product bands were identified by their coelectrophore-
sis with a range of predefined saccharide fluorotagged stand-
ards. Two image exposures were captured. The first exposure
was used for quantitation as it had all of the pixels within a lin-
ear 12-bit depth range to provide baseline data, and the sec-
ond exposure oversaturated pixel intensity to allow
identification of less abundant structures. Accurate quantita-
tion was achieved between 10 and 400 pmol of product.
Quality control was rigorously and routinely performed using a
mixture of a known concentration of fluorotagged saccharide
standards and enzyme-digested appropriate substrate con-
trols. To control for gel-to-gel variation, one cadaveric cartilage
sample was repeated when running multiple gels.
Histology and immunohistochemistry
Cryosections were stained with haematoxylin and eosin and
with toluidine blue for general histological assessment of car-
tilage and evaluation of metachromasia [3,4]. Immunostaining
was performed using monoclonal antibodies (kindly provided
by Professor Bruce Caterson, Cardiff University, UK) for chon-
droitin 4-sulphate (2-B-6), chondroitin 6-sulphate (3-B-3), and
KS (5-D-4) [3,4]. Sections were initially treated with 25 mU/ml
Table 1
Patient age and the site and size of the chondral defect treated with autologous chondrocyte implantation
Patient age (years) Site of autologous chondrocyte implantation Defect size (mm)
22 Medial femoral condyle 20 × 30
25 Lateral femoral condyle 27 × 21
25 Lateral femoral condyle 16 × 13
27 Lateral femoral condyle 30 × 40
42 Medial femoral condyle 14 × 12
44 Medial femoral condyle 18 × 15
45 Medial femoral condyle 25 × 8
52 Medial femoral condyle 21 × 13Page 3 of 10
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the proteoglycan core proteins and also aids in unmasking of
epitopes before incubating with primary antibodies. Sections
were then labelled with biotin-conjugated horse anti-mouse
immunoglobulin (Ig) G (which crossreacts with IgM; Vector
Laboratories, Burlingame, CA, USA) before incubating with
methanol and 0.3% (vol/vol) hydrogen peroxide to remove
endogenous peroxidase activity. Labelling was amplified via
avidin-peroxidase (Vectastain Elite ABC kit; Vector Laborato-
ries) and demonstrated with diaminobenzidine as substrate.
Sections that served as controls were treated with either nor-
mal mouse control IgG or phosphate-buffered saline alone, in
place of primary antibodies.
Results
FACE analysis of hyaluronidase and chondroitinase 
digestion products
Figure 1a shows a representative FACE gel showing the coe-
lectrophoresis of a known concentration of mono- and disac-
charide fluorotagged standards alongside hyaluronidase and
chondroitinase digestion products obtained from full-depth
cartilage from the lateral femoral condyle from a 30-year-old
cadaveric control. For total CS, there were ΔDi6S (88%),
ΔDi4S (9%), and ΔDi0S (3%). No other disaccharide bands
were observed. The quantities of total CS and HA disaccha-
rides (ΔDiHA) in this biopsy were determined to be 1.778 μg/
mg ± 0.005 standard deviation (SD) (n = 8) and 0.277 μg/mg
± 0.034 SD (n = 8), respectively. These data compare well
with previously published data for adult articular cartilage
[22,32]. We included this cadaveric cartilage sample when
running multiple gels to control for gel-to-gel variation. To
ensure that GAGs were not lost during processing, we per-
formed enzyme digestions with appropriate substrate controls
(data not shown).
The levels of HA disaccharides in both ACI and control groups
followed a similar trend with respect to their decrease with
increasing age (Figure 2a,b). The ACI group had an increased
concentration of HA (p < 0.05%). In the ACI group, the ΔDi4S
levels were similar to control whereas the ΔDi0S levels and
ΔDi6S levels were lower (Figure 2a,b; p < 0.05%).
Figure 1b shows a representative FACE gel showing the sep-
aration of known concentrations of mono- and disaccharide
fluorotagged standards alongside products of the analysis of
the CS termini residues. The samples were obtained from full-
depth cartilage from the medial femoral condyle from a 22-
year-old ACI patient and an age-matched cadaveric control.
For both the repair and control tissue groups, analysis of the
terminal sugars of CS identified two different nonreducing ter-
mini: GalNAc and GalNAc6S (Figure 2c,d). A significant
decrease in the concentration of both terminal sugars was
detected with advancing age. In the repair tissue, there was at
least twofold less total CS than in the control tissue.
Figure 1
Fluorophore-assisted carbohydrate electrophoresis (FACE) analysis. 
(a) Representative FACE gel of hyaluronidase and chondroitinase 
digestion products from a 30-year-old cadaveric control. Lanes A and B 
contain a mixture of predefined fluorotagged saccharide standards. 
Lane A: (1) ΔDiHA, (2) ΔDi6S, (3) ΔDi4S, (4) ΔDi2S, (5) ΔDi4,6S, (6) 
ΔDi2,6S, (7) ΔDi2,4S, (8) ΔTri2,4,6S. Lane B: (9) N-acetylgalactos-
amine (GalNAc), (10) ΔDi0S, (11) GalNAc6S, (12) GalNAc4S, (13) 4-
/6-sulphated GalNAc. Samples were digested with hyaluronidase (from 
Streptococcus dysgalactiae) (lane C) and chondroitinase ABC (lane 
D). (b) Representative FACE gel of chondroitin sulphate termini prod-
ucts from a 22-year-old cadaveric control (lane B) and a 22-year-old 
autologous chondrocyte implantation (ACI) patient (lane C). Lane A 
contains a mixture of predefined fluorotagged saccharide standards. 
Lane A: (1) GalNAc, (2) GalNAc6S, (3) GalNAc4S, (4) GalNAc4,6S, 
(5) GalNAc2,4,6S. (c) Representative FACE gel of keratanase II and 
endo-β-galactosidase digestion products obtained from full-depth carti-
lage of a 30-year-old cadaveric control (lanes E and F) and a 27-year-
old ACI patient (lanes G and H). Lanes A to D contain a mixture of pre-
defined fluorotagged saccharide standards. Lanes A to D: (1) Galβ1,2 
[fucα1,3]GlcNAc6S, (2) Galβ1,4GlcNAc6S, (3) Gal6Sβ1,4glcNAc6S, 
(4) NeuAα2,3Gal6Sβ1,4GlcNAc6S, (5) GlcNAcβ1,3Gal, (6) 
GlcNAc6Sβ1,3Gal. ΔDi0S, unsulphated chondroitin sulphate disac-
charide; ΔDi4S, chondroitin-4 sulphate disaccharide; ΔDi6S, chondroi-
tin-6 sulphate disaccharide; ΔDiHA, hyaluronan disaccharide.Page 4 of 10
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galactosidase digestion products
Figure 1c shows a representative FACE gel showing the coe-
lectrophoresis of a known concentration of saccharide fluoro-
tagged standards alongside keratanase II and endo-β-
galactosidase digestion products obtained from full-depth car-
tilage from the lateral femoral condyle from a 27-year-old ACI
patient and a 30-year-old cadaveric control. In the ACI repair
tissue group, there was a significant reduction in all digestion
products when compared with the control group (Figure 2e,f;
p < 0.05%). Only two different digestion products from the
internal KS chain were detected: Galβ1,4GlcNAc6S and
Gal6Sβ1,4glcNAc6S. Both decreased with increasing age.
We were unable to detect any terminal sugars. By contrast, in
the control group, there was a significant increase in sulpha-
tion with increasing age and four different digestion products
Figure 2
Fluorophore-assisted carbohydrate electrophoresis analysis of hyaluronidase, chondroitinase, keratanase II, and endo-β-galactosidase digestion products
products. Quantitation of levels of (a,b) hyaluronan and chondroitin sulphate (CS) disaccharides, (c,d) nonreducing terminal sugars of CS, and (e,f) 
keratan sulphate in autologous chondrocyte implantation (ACI) repair and cadaveric control tissues. Data are expressed as micrograms of disaccha-
ride per milligram of wet weight of cartilage tissue. For each biopsy, the data are presented as the mean ± standard deviation of the replicate meas-
urements. Differences between the ACI repair and cadaveric tissues were analysed using the Mann-Whitney U test (p < 0.05%). ΔDi0S, 
unsulphated chondroitin sulphate disaccharide; ΔDi4S, chondroitin-4 sulphate disaccharide; ΔDi6S, chondroitin-6 sulphate disaccharide; ΔDiHA, 
hyaluronan disaccharide; GalNAc, N-acetylgalactosamine.Page 5 of 10
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comprised mostly disulphated KS, whereas the 22- and 30-
year-old controls comprised mostly un- or monosulphated KS.
We detected the presence of one sialic-capped terminal resi-
due, NeuAα2,3Galβ1,4GlcNAc6S, in the control group.
Determination of the average chondroitin sulphate chain 
size by FACE analysis
The value for the average CS chain length was determined by
dividing the total fluorescence of the internal disaccharides by
the total fluorescence of the nonreducing termini as previously
described [33]. In the control group, the chain length was
18,208 Da ± 164 SD (Figure 3a). By contrast, CS chains in
the repair tissue were significantly shorter but approximately
the same with advancing age (4,003 ± 740 SD). Interestingly,
the exception was the 27-year-old sample, which had the long-
est CS chains (24,905 Da).
Ratio of ΔDi6S/ΔDi4S
In the control group, the ΔDi6S/ΔDi4S ratio increased with
advancing age (Figure 3b), which is in agreement with previ-
ous studies [14,32]. In the repair tissue, the ΔDi6S/ΔDi4S
ratio was significantly lower than in the control tissue and did
not alter with advancing age.
Proportion of chondroitin sulphate, hyaluronan, and 
keratan sulphate in the biopsies
FACE analysis revealed the differences in the proportions of
HA, CS, and KS between the ACI repair and cadaveric control
groups (Figure 4). Each GAG, with its constituent saccharide
component, was expressed as a total percentage of GAGs
analysed. In the repair group (Figure 4a), HA accounted for
20% to 30% of the total GAG, whereas in the control group
(Figure 4b), HA accounted for approximately 6% of the total
GAG. There was a greater proportion of CS than KS in the
repair group. The inverse was true for the control group.
Figure 3
Determination of the averaged chondroitin sulphate chain size by fluor-ophore-assisted carbohydrate electrophoresis analysis a d ratio of ΔDi6S/ΔDi4S
ophore-assisted carbohydrate electrophoresis analysis and ratio of 
ΔDi6S/ΔDi4S. Comparison of (a) number averaged chondroitin sul-
phate chain size and (b) ratio of ΔDi6S/ΔDi4S in autologous chondro-
cyte implantation (ACI) repair and cadaveric control tissues. For each 
biopsy, the data are presented as the mean ± standard deviation of the 
replicate measurements. Differences between the repair and control 
tissue were analysed using the Mann-Whitney test (*p < 0.05%). 
ΔDi4S, chondroitin-4 sulphate disaccharide; ΔDi6S, chondroitin-6 sul-
phate disaccharide.
Figure 4
Proportions of chondroitin sulphate (CS), hyaluronan (HA), and keratan sulphate (KS) in the biopsies
sulphate (KS) in the biopsies. Proportions of HA, CS, and KS in biop-
sies from (a) patients 1 year after autologous chondrocyte implantation 
and (b) controls. Each glycosaminoglycan (GAG), with its constituent 
disaccharide and monosaccharide component, is expressed as a total 
percentage of GAGs analysed by fluorophore-assisted carbohydrate 
electrophoresis.Page 6 of 10
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Histology and immunohistochemistry were used to provide a
baseline reference for comparison with FACE analysis. For the
control group, the cartilage morphology was hyaline with a
thickness of 2.15 to 2.8 mm. The sample from the 50-year-old
contained some chondrocyte clusters and apparent degener-
ation of the articulating surface in comparison with that of the
30-year-old (Figure 5). For the repair group, the cartilage mor-
phology was generally fibrocartilage (data not shown). Immu-
nohistochemistry was performed to assess GAG distribution.
The control cartilage was immunopositive for 4-sulphated CS
(2-B-6), 6-sulphated CS (3-B-3), and KS (5-D-4) with a
homogenous distribution through the matrix apart from in the
deep zone, where it was more pericellular. There was no obvi-
ous difference with age. In the ACI biopsies, immunostaining
was generally homogenous throughout for all GAGs, except in
a few biopsies where it was pericellular in the deep zone. Fig-
ures 6a and 6b show representative sections of repair tissue
from ACI patients with the highest and lowest levels of 4-sul-
phated CS as measured by FACE. There is a clear difference
in intensity of immunostaining, reflecting this. FACE analysis
demonstrated twofold less 6-sulphated CS disaccharide lev-
els in biopsies from the youngest ACI patient (22-year-old)
compared with the age-matched cadaveric control (22-year-
old). Figures 6c and 6d show that there is a slight difference
in staining intensity between these samples which is limited to
a pericellular distribution in the ACI patient but which extends
throughout the matrix generally in the control sample. These
data illustrate that the intensity of immunostaining was gener-
ally comparable with the data obtained with FACE.
Discussion
Currently, there is a lack of quantitative and qualitative bio-
chemical data regarding the nature of ACI repair tissue, partic-
ularly in humans. This is partly due to the size of the tissue
biopsy retrieved and the reluctance to disturb the repair site
following surgical repair. We are in a relatively unique position
of having access to repair tissue. In this study, we have used
FACE to analyse GAG profiles in order to further our
understanding of the composition of the repair tissue com-
pared with age- and site-matched control cartilage.
We determined that FACE can assess as little as 5 μg of car-
tilage and detect GAG saccharides and nonreducing termini
in the picomolar range. FACE has the additional benefit over
standard GAG techniques in that it enables processing and
imaging of a number of samples simultaneously. The results for
FACE analysis and intensity of immunostaining were generally
comparable. However, immunostaining cannot provide true
quantitation as staining intensity will be affected by factors
such as section thickness, antigen affinity, masking of
epitopes, effectiveness of enzyme pretreatment, or stoichiom-
etry. FACE thus offers huge advantages over immunostaining.
For example, FACE enables an estimation of the number
averaged GAG chain length. Our data demonstrate that, as an
outcome measure, FACE can not only complement but also
enhance existing histology and immunohistochemistry tech-
niques for repair tissue analysis.
The most striking finding was that 1 year after ACI surgery the
repair tissue contained half as much KS and CS as the control
tissue. These observations support previously published stud-
ies [2-8] that have reported the fibrocartilage nature of ACI
repair tissue 12 months after treatment. There could be a
number of reasons to explain this finding. Firstly, cartilage
remodelling is notoriously slow, with the half-life of aggrecan
exceeding 3 years [9,18]. Secondly, the cells present in the
defect may have a lower propensity for either specific GAG or
proteoglycan synthesis. For ACI, the cells are expanded in
culture for several passages in vitro prior to their implantation.
It is unclear how this in vitro expansion affects the cell when it
is placed into the cartilage defect. Thirdly, the GAGs that are
synthesised at an early stage may not be retained within the
repair tissue. They, along with their associated proteoglycan,
may diffuse out of the small volume of surrounding extracellular
matrix. Furthermore, there is likely to be insufficient collagen
present to entrap the proteoglycans. This commonly occurs in
the early phases of in vitro chondrocyte expansion as well as
immediately after seeding chondrocytes onto three-dimen-
sional scaffolds for tissue engineering articular cartilage
[35,36].
In the repair group, the proportion of HA was higher than in the
control group. Our values for the control group were similar to
previous FACE studies of normal cartilage [22,33]. High con-
centrations of HA are generally found during development and
the early stages of wound healing and repair [26,27]. Our
observations suggest that the cells may be producing an HA-
rich matrix to aid their migration and proliferation into the repair
site. In the control group, the HA levels decreased with
increasing age, which contrasted with a previous study using
a radiosorbent assay that assessed HA levels in maturing and
Figure 5
Control tissue stained with haematoxylin and eosin. Representative 
sections from the medial femoral condyle of (a) a 30-year-old and (b) a 
50-year-old to illustrate the surface layer in cartilage taken. The arrows 
indicate chondrocyte clusters. The bars represent 25 μm.Page 7 of 10
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increased from 20 to 30 years, reached a plateau from ages
30 to 70 years, and increased slightly after 70 years. It is diffi-
cult to compare our data with that study since we have such a
small sample size.
In the repair group, the CS chains were considerably shorter.
Variations in CS chain length can be induced during atypical
proteoglycan synthesis. In addition, shorter chains have been
linked with cartilage degeneration [14] but there is still a pau-
city of data from human subjects. These changes may be
important for cartilage homeostasis. In the present study, CS
content and the ratio of ΔDi6S/ΔDi4S were lower in the repair
tissue. Functional implications of CS sulphation in cartilage
have yet to be elucidated. However, changes in sulphation lev-
els and patterns are known to be influenced by both mechan-
ical loading and metabolic activity. During normal cartilage
maturation, CS undergoes major changes in sulphation up to
the age of 20 years; ΔDi6S content increases whilst ΔDi4S
content decreases [14]. After the age of 20, both ΔDi6S and
ΔDi4S content remain fairly constant but there are distribution
changes within different cartilage zones. Unfortunately, we
had insufficient ACI repair tissue available to perform a zonal
analysis. It is important to emphasise that we have analysed
only 1-year post-ACI biopsies from discrete regions and that
the repair tissue profile may be very different at earlier or later
time points. In this study, we detected two CS termini saccha-
rides: galNAc and galNAc6s. Several other groups
[17,31,32,37,38] have assessed the nonreducing termini res-
idues in human CS by means of either biosynthetic or chemi-
cal techniques. None of the groups examined the CS termini
from an equivalent age range (22 to 52 years) and conse-
quently it is difficult to make direct comparisons with our data.
The KS digestion products identified in this study corre-
sponded to those detected by previous investigations employ-
ing FACE [13]. The results obtained illustrate that there is less
KS in ACI repair tissue and that it is more sulphated when
compared with the control. Lower KS levels could be associ-
ated with the monolayer in vitro expansion of chondrocytes
prior to ACI. It has been reported that KS synthesis decreases
or stops when chondrocytes assume a fibroblastic morphol-
Figure 6
Immunohistochemistry to assess glycosaminoglycan distribution. Cartilage sections immunohistochemically stained for (a,b) chondroitin-4-sulphate 
and (c,d) chondroitin-6-sulphate. Repair tissue from autologous chondrocyte implantation (ACI)-treated patients with the highest (a) (22-year-old) 
and lowest (b) (52-year-old) levels of chondroitin-4-sulphate measured by fluorophore-assisted carbohydrate electrophoresis (FACE). Biopsies of 
cartilage from a 22 yr old ACI patient (c) and its age-matched control (d) immunostained for chondroitin 6-sulphate. The pattern of immunostaining in 
repair tissue from the ACI-treated patient (c) with the highest levels of chondroitin-6-sulphate as measured by FACE demonstrated a pericellular pat-
tern, similar to that seen in the age-matched cadaveric control tissue but there was also more widespread matrix staining (d).Page 8 of 10
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likely to be because the repair tissue is predominantly fibrocar-
tilaginous, less like mature articular cartilage, and hence
producing less KS. Furthermore, in articular cartilage, there is
an increase in the proportion of KS with increasing age [9,39].
Hence, this tissue resembles younger and less mature or aged
tissue. More sulphated KS chains could be the result of over-
synthesis during tissue repair or they could indicate a level of
fine modulation which may be necessary for tissue function.
The sulphation levels of KS chains isolated from young carti-
lage (5 to 11 years old) have been shown to increase from
30%–50% to 80%–95% with advancing age [13]. We
detected the presence of one sialic-capped terminal residue
(NeuAα2,3Galβ1,4GlcNAc6S), which is in agreement with
previously published work [13] that reported that sulphation of
the terminal capping structures increases with maturity.
In this study, we have demonstrated that repair tissue formed
after ACI has a lower concentration of GAGs, with very little
KS, less chondroitin 6-sulphate, and shorter CS chains than
site- and age-matched cadaveric articular cartilage. In con-
trast, ACI repair tissue has higher levels of HA than the con-
trols. Thus, the repair tissue has some significant differences
from normal adult articular cartilage.
Conclusion
Currently, there is a paucity of biochemical data to determine
whether ACI produces durable repair tissue. We are in a rela-
tively unique position of having access to repair tissue 1 year
post-ACI as well as age-matched cadavers. In the ACI repair
tissue, there was an overall reduction in GAG content and the
GAG populations differed from controls. These changes
suggest that the composition of the repair tissue is not identi-
cal to mature articular cartilage. Further studies of long-term
ACI patients are necessary to determine whether GAGs influ-
ence the long-term durability of repair tissue.
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